Literature DB >> 19808101

Thyroid hormone and atherosclerosis.

Toshihiro Ichiki1.   

Abstract

It is generally accepted that the euthyroid state is preferred for the cardiovascular system because both hyperthyroidism and hypothyroidism cause or accelerate cardiovascular diseases. And hypothyroidism is known to be associated with atherosclerosis and ischemic heart diseases. The accelerated atherosclerosis in hypothyroid state has been traditionally ascribed to atherogenic lipid profile, diastolic hypertension and impaired endothelial function. In addition, recent studies suggest that hypothyroidism is associated with the emerging risk factors for atherosclerosis such as hyperhomocysteinemia and an increase in C-reactive protein level. Thyroid hormone also has direct anti-atherosclerotic effects such as blood vessel dilatation, production of vasodilatory molecules, and inhibition of angiotensin II receptor expression and its signal transduction. These data suggest that thyroid hormone inhibits atherogenesis through direct effects on the vasculature as well as modifying risk factors for atherosclerosis. This review summarizes the basic and clinical studies on the role of thyroid hormone in atherogenesis and a possible application of thyroid hormone mimetics for the therapy of hypercholesterolemia and atherosclerosis. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19808101     DOI: 10.1016/j.vph.2009.09.004

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  31 in total

Review 1.  Therapeutic approaches to drug targets in atherosclerosis.

Authors:  Prasad G Jamkhande; Prakash G Chandak; Shashikant C Dhawale; Sonal R Barde; Priti S Tidke; Ram S Sakhare
Journal:  Saudi Pharm J       Date:  2013-11-05       Impact factor: 4.330

2.  TSH stimulates the proliferation of vascular smooth muscle cells.

Authors:  Limin Tian; Jing Ni; Tiankang Guo; Jing Liu; Yamei Dang; Qian Guo; Luyan Zhang
Journal:  Endocrine       Date:  2014-01-23       Impact factor: 3.633

3.  Clinical outcomes of patients with hypothyroidism undergoing percutaneous coronary intervention.

Authors:  Ming Zhang; Jaskanwal D S Sara; Yasushi Matsuzawa; Hossein Gharib; Malcolm R Bell; Rajiv Gulati; Lilach O Lerman; Amir Lerman
Journal:  Eur Heart J       Date:  2016-01-12       Impact factor: 29.983

4.  Thyroid hormone status regulates the expression of secretory phospholipases.

Authors:  Pragya Sharma; Tania Levesque; Eric Boilard; Edwards A Park
Journal:  Biochem Biophys Res Commun       Date:  2014-01-16       Impact factor: 3.575

5.  Nuclear corepressors mediate the repression of phospholipase A2 group IIa gene transcription by thyroid hormone.

Authors:  Pragya Sharma; Shalini Thakran; Xiong Deng; Marshall B Elam; Edwards A Park
Journal:  J Biol Chem       Date:  2013-04-29       Impact factor: 5.157

6.  Evaluation of epicardial fat tissue thickness in patients with hyperthyroidism.

Authors:  Emine Binnetoğlu; Mehmet Asik; Burak Altun; Hacer Sen; Emine Gazi; Gökhan Erbağ; Fahri Günes; Yıldız Garip Bilen; Ahmet Temiz; Ahmet Barutçu; Adem Bekler
Journal:  Wien Klin Wochenschr       Date:  2014-08-19       Impact factor: 1.704

7.  Evaluation of the effect of L-thyroxin therapy on endothelial functions in patients with subclinical hypothyroidism.

Authors:  Fatma Alibaz Oner; Selen Yurdakul; Ender Oner; Ayse Kubat Uzum; Mecdi Erguney
Journal:  Endocrine       Date:  2011-04-20       Impact factor: 3.633

Review 8.  Cardiovascular comorbidity in rheumatic diseases.

Authors:  Michael T Nurmohamed; Maaike Heslinga; George D Kitas
Journal:  Nat Rev Rheumatol       Date:  2015-08-18       Impact factor: 20.543

9.  Subclinical hypothyroidism and risk for incident ischemic stroke among postmenopausal women.

Authors:  Ayush Giri; Todd L Edwards; Vicky A LeGrys; Carol E Lorenz; Michele Jonsson Funk; Robin Schectman; Gerardo Heiss; Jennifer G Robinson; Katherine E Hartmann
Journal:  Thyroid       Date:  2014-06-16       Impact factor: 6.568

10.  Fetuin-A levels in hyperthyroidism.

Authors:  Bariş Onder Pamuk; Hamiyet Yilmaz; Tugba Topcuoglu; Oktay Bilgir; Ozlem Çalan; Gulseren Pamuk; Derun Taner Ertugrul
Journal:  Clinics (Sao Paulo)       Date:  2013       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.